Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05283629 · ClinicalTrials.gov registry record · NA

nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

A NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment, sponsored by University of Massachusetts, Worcester.

Active
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05283629 is a NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment that is active but no longer recruiting, run by University of Massachusetts, Worcester. The registered enrollment target is 50 participants, below the 87-participant average among 4 other Chemo-brain trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05283629, a NA study of Chemo-brain and Chemotherapy-Related Cognitive Impairment, is active but no longer recruiting, sponsored by University of Massachusetts, Worcester.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).

Interventions

  • BEHAVIORAL Neuroplasticity-based Computerized Cognitive Remediation
  • BEHAVIORAL Active Control Condition

Study Locations (1)

Massachusetts

  • UMass Chan Medical School - Worcester

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-08-01
Est. Completion 2030-03-01
Phase NA

What the Registry Record Tells You About NCT05283629

The ClinicalTrials.gov registry entry for NCT05283629 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 4 other Chemo-brain trials with a reported enrollment target (43% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chemo-brain appearing as the primary indexed condition, and to 2 interventions - of which Neuroplasticity-based Computerized Cognitive Remediation is the first listed.

NCT05283629 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05283629 about?

NCT05283629 is a clinical study titled "nCCR for Chemotherapy Related Cognitive Impairment Randomized Study". The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).

What is the current status of trial NCT05283629?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-08-01. Estimated completion is 2030-03-01.

What conditions does trial NCT05283629 study?

This clinical trial studies the following conditions: Chemo-brain, Chemotherapy-Related Cognitive Impairment.

What interventions are being tested in trial NCT05283629?

The interventions under investigation include: Neuroplasticity-based Computerized Cognitive Remediation (BEHAVIORAL), Active Control Condition (BEHAVIORAL).

Who is sponsoring clinical trial NCT05283629?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05283629 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chemo-brain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.